BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bergqvist V, Holmgren J, Klintman D, Marsal J. Real-world data on switching from intravenous to subcutaneous vedolizumab treatment in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2022;55:1389-401. [PMID: 35470449 DOI: 10.1111/apt.16927] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Bergqvist V, Holmgren J, Klintman D, Marsal J. Letter: to switch or not to switch, that is the question-author's reply. Aliment Pharmacol Ther 2022;56:922-3. [PMID: 35934847 DOI: 10.1111/apt.17147] [Reference Citation Analysis]
2 Bresteau C, Martin A, Amiot A. Letter: to switch or not to switch, that is the question. Aliment Pharmacol Ther 2022;56:920-1. [PMID: 35934860 DOI: 10.1111/apt.17112] [Reference Citation Analysis]
3 Volkers A, Straatmijer T, Duijvestein M, Sales A, Levran A, van Schaik F, Maljaars J, Gecse K, Ponsioen C, Grootjans J, Hanzel J, Tack G, Jansen J, Hoentjen F, de Boer N, van der Marel S, Dijkstra G, Oldenburg B, Löwenberg M, van der Meulen A, D′haens G; IBD center Amsterdam and the Dutch Initiative on Crohn and Colitis. Real‐world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases. Aliment Pharmacol Ther. [DOI: 10.1111/apt.17153] [Reference Citation Analysis]
4 Nadesalingam V, Subramanian S. Editorial: intravenous to subcutaneous vedolizumab-switch without glitch! Aliment Pharmacol Ther 2022;56:349-50. [PMID: 35748843 DOI: 10.1111/apt.16989] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
5 Bergqvist V, Holmgren J, Klintman D, Marsal J. Editorial: intravenous to subcutaneous vedolizumab-switch without glitch! Authors' reply. Aliment Pharmacol Ther 2022;56:351-2. [PMID: 35748834 DOI: 10.1111/apt.17073] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]